🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)

RecruitingNAAges 19 Years - anyAllChonnam National University Hospital
NCT04968808 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \[PCI\] for both infarct-related artery \[IRA\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 19 years old 2. Non-ST-segment elevation myocardial infarction * Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and, * occurs at rest, usually lasting \> 10 minutes * severe and new onset (within the prior 4-6 weeks) * crescendo pattern * Elevated cardiac biomarkers and, * ≥ 99% value of high-sensitivity cardiac troponin * No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram 3. PCI within 72 hours after symptom development 4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation 5. Patient's or protector's agreement about study design and the risk of PCI Exclusion Criteria: 1. Cardiogenic shock at initial presentation or after treatment of IRA 2. TIMI flow at non-IRA ≤ 2 3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision 4. Non-IRA lesion not suitable for PCI treatment by operators' decision 5. Chronic total occlusion at non-IRA 6. History of anaphylaxis to contrast agent 7. Pregnancy and lactation 8. Life expectancy \< 1-year 9. Severe valvular disease 10. History of CABG, or planned CABG 11. Fibrinolysis before admission
💊

What it tests

  • Staged in-hospital complete revascularization
  • Immediate complete revascularization
📍

Where

1 site
Chonnam National University Hospital
Gwangju, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy